Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (82014)	3/16/2001 1:11:24 PM
From: Jim Bishop	Respond to of 150070

UNVC shake coming, but WEIN spoiled NITE's little ploy.

To: Joe Copia who wrote (82014)	3/16/2001 11:15:31 PM
From: Jim Bishop	Respond to of 150070

UNVC thinking out loud here....... ... okay I can understand people not wanting to hold anything over a weekend in this nutty market, and UNVC took a little momo ride on record volume on the news today...... spread got ugly......profit taking etc..... And I know they have yet to show a profit. And I know there is dilution, and more coming. BUT.....from the filings and more: "We expect to continue to incur operating losses until such time, if ever, as we derive significant increases in revenues from the sale of our locking clip syringes and sale of equipment and licencing (sic) technology." Well it appears to me that this deal with GSK kinda ensures that there will be signifiicant increases in revenues from the syringes. gsk.com GSK is no puny little company and I don't think they would select UNVC's syringes by flipping a coin, and I don't think they would select a company to supply them with syringes unless they were confident of supply. "In 2000, the company distributed over 1.1 billion doses of vaccines to 177 countries, an average of 35 doses a second." "GSK Biologicals will start supplying all vials of liquid pediatric vaccines with A-D syringes to countries including Africa, the Caribbean, Latin America, Eastern Europe, Middle East, South East and South West Asia and other emerging markets." public.wsj.com LONDON -- GlaxoSmithKline PLC reported a 13% rise in 2000 pretax profit, boosted by a 10% increase in pharmaceutical sales and double-digit growth in key therapy areas for the recently formed group. In its first earnings report since the merger of Glaxo Wellcome and SmithKline Beecham, the company said Wednesday that its pretax profit after one-time items rose to 5.33 billion pounds ($7.71 billion) on a pro forma basis from 4.71 billion pounds a year earlier. Ummm, that's pretax PROFIT of $7.71 BILLION, AMERICAN DOLLARS And these guys, with 900 research scientists in their employ, picked little UNVC's auto-disable (A-D) syringes as the unit to deliver "all vials of it's liquid pediatric vaccines" to developing countries. " It is now WHO-UNICEF policy that the A-D syringe is the equipment of choice for administering vaccines, both in routine immunization and in mass vaccination campaigns" Time will tell.